AcquisitionsJul 27, 2026, 01:02 AM
argenx to Acquire Forte Biosciences for $2.2B
AI Summary
argenx announced a definitive agreement to acquire Forte Biosciences for approximately $2.2 billion, paying $77 per share in cash. This acquisition, representing an 86% premium, strengthens argenx's immunology portfolio by adding FB102, Forte Biosciences' lead anti-CD122 antibody program. FB102 has shown clinical proof-of-concept in vitiligo and celiac disease, with potential for other autoimmune conditions, aligning with argenx's strategy to address diseases with unmet needs. The transaction is expected to close in the third quarter of 2026.
Key Highlights
- argenx to acquire Forte Biosciences for $77 per share in cash.
- Total equity value of the acquisition is approximately $2.2 billion.
- The offer represents an 86% premium to Forte Biosciences' VWAP since July 9, 2026.
- Acquisition includes FB102, Forte Biosciences' lead anti-CD122 antibody program.
- FB102 has clinical proof-of-concept in vitiligo and celiac disease.
- The transaction is expected to close in Q3 2026.
Price Impact
More from ARGX